{"disease":{"id":"appendiceal-cancers","name":"appendiceal cancers"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT07060014","title":"NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"The Methodist Hospital Research Institute","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}